CaReS® (MACT) versus microfracture in treating symptomatic patellofemoral cartilage defects: a retrospective matched-pair analysis

Petri, Maximilian; Broese, Maximilian; Simon, Annika; Liodakis, Emmanouil; Ettinger, Max; Guenther, Daniel; Zeichen, J.; Krettek, Christian; Jagodzinski, Michael; Haasper, Carl

doi:10.1007/s00776-012-0305-x

Cited by 51 publications

(48 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We had comparable results with the predecessor product in patellar defects which was cell based [5]. However, compared to microfracture there were no benefits detectable in our series.…”

supporting

confidence: 53%

Comment on Roessler et al.: Short-term follow up after implantation of a cell-free collagen type I matrix for the treatment of large cartilage defects of the knee

Haasper

2015

International Orthopaedics (SICOT)

Self Cite

View full text Add to dashboard Cite

“…We had comparable results with the predecessor product in patellar defects which was cell based [5]. However, compared to microfracture there were no benefits detectable in our series.…”

supporting

confidence: 53%

Comment on Roessler et al.: Short-term follow up after implantation of a cell-free collagen type I matrix for the treatment of large cartilage defects of the knee

Haasper

2015

International Orthopaedics (SICOT)

Self Cite

View full text Add to dashboard Cite

“…However, histological analysis of these constructs at 1 year in a minipig model indicates that they promote hyaline cartilage formation (108). When compared to microfracture, a small retrospective study (n=20) indicated no differences between the two treatment options (116). CaReS ® has been used in select European countries and is also approved in Iran, Turkey, and China.…”

Section: Tissue Engineered Articular Cartilage Productsmentioning

confidence: 99%

Cell-based tissue engineering strategies used in the clinical repair of articular cartilage

2016

View full text Add to dashboard Cite

One of the most important issues facing cartilage tissue engineering is the inability to move technologies into the clinic. Despite the multitude of review articles on the paradigm of biomaterials, signals, and cells, it is reported that 90% of new drugs that advance past animal studies fail clinical trials (1). The intent of this review is to provide readers with an understanding of the scientific details of tissue engineered cartilage products that have demonstrated a certain level of efficacy in humans, so that newer technologies may be developed upon this foundation. Compared to existing treatments, such as microfracture or autologous chondrocyte implantation, a tissue engineered product can potentially provide more consistent clinical results in forming hyaline repair tissue and in filling the entirety of the defect. The various tissue engineering strategies (e.g., cell expansion, scaffold material, media formulations, biomimetic stimuli, etc.) used in forming these products, as collected from published literature, company websites, and relevant patents, are critically discussed. The authors note that many details about these products remain proprietary, not all information is made public, and that advancements to the products are continuously made. Nevertheless, by fully understanding the design and production processes of these emerging technologies, one can gain tremendous insight into how to best use them and also how to design the next generation of tissue engineered cartilage products.

show abstract

“…2) [16][17][18][19]. Заметим, что свойства созданной с помощью клеточных технологий хрящевой ткани определя-ются многими параметрами, в том числе источни-ком клеток, типом скаффолда для прикрепления клеток, методом посева клеток, составом культу-ральной среды, доступом питательных веществ, факторами дифференцировки и механической сти-муляцией [20,21].…”

Section: технологии стимулирования регенерации поврежденной хрящевunclassified

Tissue Engineering and Regenerative Medicine Technologies in the Treatment of Articular Cartilage Defects

Басок

Севастьянов

2017

RJTAO

View full text Add to dashboard Cite

1 ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России, Москва, Российская Федерация 2 АНО «Институт медико-биологических исследований и технологий», Москва, Российская Федерация Важнейшими проблемами здравоохранения в индустриальном обществе являются повреждение и деге-нерация суставного хряща, что связано с ограниченными возможностями ткани к регенерации. В обзоре подробно описаны существующие и разрабатываемые технологии восстановления и замещения повреж-денных хрящевых тканей суставов. Дан анализ полученных результатов по двум основным направлени-ям: стимулирование регенерации поврежденной хрящевой ткани и выращивание элементов хрящевой ткани в биореакторах.Ключевые слова: суставной хрящ, клеточно-и тканеинженерные конструкции, регенеративная медицина, биореакторы. TISSUE ENGINEERING AND REGENERATIVE MEDICINE TECHNOLOGIES IN THE TREATMENT OF ARTICULAR CARTILAGE DEFECTS

show abstract

CaReS® (MACT) versus microfracture in treating symptomatic patellofemoral cartilage defects: a retrospective matched-pair analysis

Cited by 51 publications

References 32 publications

Comment on Roessler et al.: Short-term follow up after implantation of a cell-free collagen type I matrix for the treatment of large cartilage defects of the knee

Comment on Roessler et al.: Short-term follow up after implantation of a cell-free collagen type I matrix for the treatment of large cartilage defects of the knee

Cell-based tissue engineering strategies used in the clinical repair of articular cartilage

Tissue Engineering and Regenerative Medicine Technologies in the Treatment of Articular Cartilage Defects

Contact Info

Product

Resources

About